Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q9UIJ5 (
Rec
)
58,342
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although palmitoylation markedly affects tetraspanin protein biochemistry and functions, relevant palmitoylating enzymes were not known. There are 23 mammalian "DHHC" (Asp-His-His-Cys) proteins, which presumably palmitoylate different sets of protein substrates. Among DHHC proteins tested,
DHHC2
best stimulated palmitoylation of tetraspanins CD9 and
CD151
, whereas inactive
DHHC2
(containing DH-->AA or C-->S mutations within the DHHC motif) failed to promote palmitoylation. Furthermore,
DHHC2
associated with CD9 and
CD151
, but not other cell surface proteins, and
DHHC2
knockdown diminished CD9 and
CD151
palmitoylation. Knockdown of six other Golgi-resident DHHC proteins (DHHC3, -4, -8, -17, -18, and -21) had no effect on CD9 or
CD151
.
DHHC2
selectively affected tetraspanin palmitoylation, but not the palmitoylations of integrin beta4 subunit and bulk proteins visible in [(3)H]palmitate-labeled whole cell lysates.
DHHC2
-dependent palmitoylation also had multiple functional effects. First, it promoted physical associations between CD9 and
CD151
, and between alpha3 integrin and other proteins. Second, it protected
CD151
and CD9 from lysosomal degradation. Third, the presence of
DHHC2
, but not other DHHC proteins, shifted cells away from a dispersed state and toward increased cell-cell contacts.
...
PMID:DHHC2 affects palmitoylation, stability, and functions of tetraspanins CD9 and CD151. 1850 21